NeuroSense Therapeutics (NRSN) Competitors $1.24 +0.06 (+5.08%) Closing price 03:59 PM EasternExtended Trading$1.22 -0.02 (-1.94%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRSN vs. VNRX, ANL, ALXO, CLNN, HYPD, IMMX, APLT, CVM, PEPG, and ALGSShould you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include VolitionRx (VNRX), Adlai Nortye (ANL), ALX Oncology (ALXO), Clene (CLNN), Hyperion DeFi (HYPD), Immix Biopharma (IMMX), Applied Therapeutics (APLT), CEL-SCI (CVM), PepGen (PEPG), and Aligos Therapeutics (ALGS). These companies are all part of the "pharmaceutical products" industry. NeuroSense Therapeutics vs. Its Competitors VolitionRx Adlai Nortye ALX Oncology Clene Hyperion DeFi Immix Biopharma Applied Therapeutics CEL-SCI PepGen Aligos Therapeutics NeuroSense Therapeutics (NASDAQ:NRSN) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Is NRSN or VNRX more profitable? NeuroSense Therapeutics has a net margin of 0.00% compared to VolitionRx's net margin of -2,321.14%. Company Net Margins Return on Equity Return on Assets NeuroSense TherapeuticsN/A N/A -445.40% VolitionRx -2,321.14%N/A -163.39% Do insiders and institutionals hold more shares of NRSN or VNRX? 1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 8.1% of VolitionRx shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Comparatively, 10.4% of VolitionRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate NRSN or VNRX? NeuroSense Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 1,029.03%. VolitionRx has a consensus target price of $3.50, suggesting a potential upside of 478.51%. Given NeuroSense Therapeutics' higher probable upside, research analysts plainly believe NeuroSense Therapeutics is more favorable than VolitionRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, NRSN or VNRX? NeuroSense Therapeutics has higher earnings, but lower revenue than VolitionRx. VolitionRx is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroSense TherapeuticsN/AN/A-$10.21M-$0.54-2.30VolitionRx$1.32M49.34-$35.32M-$0.25-2.42 Does the media favor NRSN or VNRX? In the previous week, NeuroSense Therapeutics had 1 more articles in the media than VolitionRx. MarketBeat recorded 1 mentions for NeuroSense Therapeutics and 0 mentions for VolitionRx. NeuroSense Therapeutics' average media sentiment score of 1.91 beat VolitionRx's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Overall Sentiment NeuroSense Therapeutics Very Positive VolitionRx Neutral Which has more volatility and risk, NRSN or VNRX? NeuroSense Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. SummaryNeuroSense Therapeutics beats VolitionRx on 7 of the 13 factors compared between the two stocks. Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRSN vs. The Competition Export to ExcelMetricNeuroSense TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.95M$3.11B$5.66B$10.37BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-2.3021.3275.7526.15Price / SalesN/A454.84560.95125.53Price / CashN/A45.2537.6061.28Price / Book6.539.7412.416.36Net Income-$10.21M-$52.93M$3.29B$270.97M7 Day Performance1.64%3.87%1.26%0.36%1 Month Performance10.72%7.65%3.84%6.37%1 Year Performance-2.36%20.14%61.01%28.46% NeuroSense Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRSNNeuroSense Therapeutics2.6583 of 5 stars$1.24+5.1%$14.00+1,029.0%-1.7%$16.95MN/A-2.3010Positive NewsUpcoming EarningsVNRXVolitionRx1.552 of 5 stars$0.62-9.5%$3.50+469.0%-2.7%$66.18M$1.32M-1.7180Positive NewsGap DownANLAdlai Nortye1.9466 of 5 stars$1.69-4.3%$9.00+432.5%-17.6%$65.17M$5M0.00127Positive NewsGap DownHigh Trading VolumeALXOALX Oncology3.6559 of 5 stars$1.27+5.0%$3.30+159.8%-1.1%$64.80MN/A-0.5840Positive NewsCLNNClene3.1706 of 5 stars$6.40+0.2%$32.60+409.4%+26.2%$64.35M$340K-1.70100News CoverageAnalyst ForecastGap DownHYPDHyperion DeFi0.4585 of 5 stars$10.16-9.9%$2.00-80.3%-77.3%$64.24M$60K-0.1740News CoverageGap UpIMMXImmix Biopharma3.1099 of 5 stars$2.24+2.3%$8.00+257.1%+23.6%$63.15MN/A-2.919APLTApplied Therapeutics3.8218 of 5 stars$0.48+9.5%$4.13+767.0%-93.3%$62.60M$460K-1.0630News CoveragePositive NewsGap UpCVMCEL-SCI0.7328 of 5 stars$8.99+3.7%N/A-73.0%$61.87MN/A-18.7343PEPGPepGen3.3945 of 5 stars$2.12+12.8%$7.25+242.0%-31.7%$61.66MN/A-0.7230Trending NewsAnalyst ForecastGap DownALGSAligos Therapeutics3.861 of 5 stars$9.53-1.4%$50.00+424.7%+13.9%$59.48M$3.94M-0.4890 Related Companies and Tools Related Companies VNRX Competitors ANL Competitors ALXO Competitors CLNN Competitors HYPD Competitors IMMX Competitors APLT Competitors CVM Competitors PEPG Competitors ALGS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRSN) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRSN Stock Alerts